SCINAI IMMUNOTHERAPEUTICS LT (SCNI) Stock Earnings & Estimates
NASDAQ:SCNI - US09073Q3039 - ADR
1.46 USD
-0.02 (-1.35%)
1.46 USD
0 (0%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | ||
|---|---|---|---|---|
| Revenue YoY % growth | 658K | |||
| EBITDA YoY % growth | -10.499M -4.62% | -9.192M 12.45% | -6.989M 23.97% | |
| EBIT YoY % growth | -11.061M -2.58% | -9.706M 12.25% | -8.638M 11.00% | |
| Operating Margin | N/A | N/A | -1,312.77% | |
| EPS YoY % growth | N/A 99.93% | -18.70 -61,011.11% | N/A 98.91% |
All data in USD
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2023 Q2Q % growth | -4.70 -4,507.84% | -6.32 | 1.62 | 25.68% |
| Q3 2023 Q2Q % growth | 8.00 7,900.00% | -10.10 | 18.10 | 179.22% |
| Q2 2023 Q2Q % growth | -11.10 -455.00% | -9.28 | -1.82 | -19.59% |
| Q1 2023 Q2Q % growth | -10.90 45.50% | -7.45 | -3.45 | -46.39% |
| Q4 2022 Q2Q % growth | 99.62% | -0.10 | % | |
| Q3 2022 Q2Q % growth | 0.10 | -1.02 | 1.12 | 109.80% |
| Q2 2022 Q2Q % growth | -2.00 | -10.71 | 8.71 | 81.33% |
| Q1 2022 Q2Q % growth | -20.00 | -10.20 | -9.80 | -96.08% |
| Q4 2021 Q2Q % growth | -27.00 | -8.67 | -18.33 | -211.42% |
| Q2 2020 Q2Q % growth | -114.00 44.12% | -1.02 | -112.98 | -11,076.47% |
| Q1 2020 Q2Q % growth | -10.00 | -1.02 | -8.98 | -880.39% |
| Q3 2019 Q2Q % growth | -80.00 | -3.06 | -76.94 | -2,514.38% |
| Q2 2019 Q2Q % growth | -204.00 | -2.04 | -201.96 | -9,900.00% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A |
| Revenue | N/A | N/A | N/A | N/A |